Jaguar Health's Crofelemer Shows Promise in Chronic Refractory Diarrhea Treatment

Jaguar Health's investigational drug, crofelemer, has shown positive results in treating chronic refractory diarrhea, according to presentations at the American College of Gastroenterology Annual Scientific Meeting. Two studies highlighted its potential benefits for patients with functional and idiopathic diarrhea, both without substantial side effects. The drug, derived from the Croton lechleri tree, targets diarrhea without causing constipation, making it a promising option for treatment.

In a small study of functional diarrhea patients, crofelemer significantly decreased stool consistency and abdominal pain. A second study on chronic idiopathic diarrhea showed a 58.8% improvement in patients. With about 10-15% of Americans affected by IBS, these findings could impact many individuals. However, larger trials are needed to confirm safety and efficacy.

Jaguar Health plans to continue exploring crofelemer's potential, aiming to improve quality of life for those suffering from intractable diarrhea conditions. The studies support ongoing efforts to address unmet needs in gastrointestinal treatment.